Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020
August 18 2020 - 4:05PM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage
biotechnology company developing a new generation of human enzyme
therapeutics as innovative solutions for rare and other high-burden
diseases, today announced it will participate in two presentations
at the World Orphan Drug Congress USA 2020 being held virtually
August 24-27, 2020.
Presentation Details
Panel Title: Stronger Together: Continuing industry and
patient partnerships to ensure inclusion of patient voice along the
full continuum of development, from pre-clinical through
commercializationDate/Time: August 24 at 9:10 a.m. EDT
Moderator: Michael C. Hanley, Aeglea’s chief commercial officer
Presentation Title: Next generation human enzymes: Innovative
solutions for patients with rare diseasesDate/Time: August 25 at
12:50 p.m. EDTPresenter: Anthony G. Quinn, M.B. Ch.B., Ph.D.,
Aeglea’s president and chief executive officer
The company presentation will be available for download on the
Presentations & Events section of the Company’s website.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare and other high burden diseases. Aeglea's lead
product candidate, pegzilarginase, is in a pivotal Phase 3 trial
for the treatment of Arginase 1 Deficiency and has received both
Rare Pediatric Disease and Breakthrough Therapy Designation. The
Company initiated a Phase 1/2 clinical trial of ACN00177 for the
treatment of Homocystinuria in the second quarter of 2020. Aeglea
has an active discovery platform, with the most advanced program
for Cystinuria. For more information, please visit
http://aegleabio.com.
Media Contact:Kelly Boothe, Ph.D.Director,
Corporate CommunicationsAeglea BioTherapeutics 512.399.5458
media@aegleabio.com
Investor Contact:Joey PerroneSenior Director,
Finance & Investor RelationsAeglea
BioTherapeuticsinvestors@aegleabio.com
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Apr 2023 to Apr 2024